Recs

4

When Binary Events Become Biotech Bloodbaths

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Biotech investors live for the binary event, when a single piece of news -- be it a trial result or an FDA decision -- can instantly double an investment. Take buyout candidate Theravance (Nasdaq: THRX  ) , which recently popped 20% on news that GlaxoSmithKline (NYSE: GSK  ) upped its stake in the small biotech to 27%.

But with the possibility of sudden riches comes big risks -- risks that new investors drawn to seemingly easy gains sometimes fail to grasp. Consider these three biotech bloodbaths from just this week a convenient reminder.

First up is the less-than-dynamic duo of Keryx Biopharmaceuticals (Nasdaq: KERX  ) and AEterna Zentaris (Nasdaq: AEZS  ) . Hopes were sky high that lead drug candidate perifosine would ace a phase 3 trial dubbed X-PECT focusing on a subset of the phase 2 trial's most receptive patients. I'm guessing investors in either biotech didn't X-PECT a 65% share-price drop, but that's what happened when perfosine couldn't meet its goal.

Perifosine's failure treating colorectal cancer hasn't doomed the drug to the waste bin -- yet. But the drug's phase 3 trial for multiple myeloma is in jeopardy as the management "carefully evaluates" it, citing recruitment difficulty. There was no word yet about its phase 2 trials treating several other cancers.

AVI BioPharma (Nasdaq: AVII  ) , which saw a near 30% decline in its shares, is a slightly different animal. Its muscular dystrophy drug etepliersen worked at a biological level by increasing dystrophin-containing muscle fibers, but not where it mattered: helping patients walk. With AVI's expensive phase 3 trial on the horizon, only $40 million in the bank, and cash burn approaching $35 million over the past 12 months, investors sticking with this stock can probably look forward to dilution.

For investors holding on to an investment suddenly worth significantly less, there is a glimmer of hope. As usual, when a trial goes poorly, biotechs tend to focus on the positives. Both Keryx and AEterna touted other drugs in their pipelines. For Keryx, it's Zerenex in phase 3 trials, and for AEterna, its more robust pipeline includes AEZS-130 and AEZS 108 in phase 3 and phase 2 development. AVI management, gearing up for a phase 3 trial, is optimistic that over a longer regimen patients could see tangible results.

However, these companies live off hope, so don't just look at the sell-off and assume shares are cheap. Do your homework, understand the risks involved, and have a firm grasp on what you can afford to lose, if a binary event turns into a biotech bloodbath.

A better approach
Motley Fool co-founder David Gardner recently identified a small-cap health-care company that is poised for monster returns, without worrying about trial failures. To uncover this top pick today, take a look at our special free report, "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Access your report -- it's totally free.

David Williamson holds no position in any company mentioned. Check out his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of GlaxoSmithKline. The Motley Fool has a disclosure policy. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.


Read/Post Comments (1) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 06, 2012, at 8:30 PM, Yrral13 wrote:

    Another pro GSK article bashing a competitor............no conflict ? you fools

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1854802, ~/Articles/ArticleHandler.aspx, 8/5/2015 12:28:57 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

David Williamson
TMFGreenwave

The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...

Today's Market

updated 3 hours ago Sponsored by:
DOW 17,550.69 -47.51 -0.27%
S&P 500 2,093.32 -4.72 -0.22%
NASD 5,105.55 -9.84 -0.19%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/4/2015 3:58 PM
AEZS $0.18 Down +0.00 -0.99%
Aeterna Zentaris,… CAPS Rating: ****
GSK $43.45 Down -0.06 -0.14%
GlaxoSmithKline CAPS Rating: ****
KERX $7.34 Down -0.16 -2.13%
Keryx Biopharmaceu… CAPS Rating: **
SRPT $32.75 Down -0.75 -2.24%
Sarepta Therapeuti… CAPS Rating: ***
THRX $14.68 Down -0.25 -1.67%
Theravance, Inc. CAPS Rating: ***

Advertisement